Printed from the IBC Life Sciences Web site on February 10, 2012 3:44 AM ET.
Page location: http://www.ibclifesciences.com/antibodyprod/overview.xml
Online Registration is Open!
Mix-and-match sessions from these additional co-located conferences at no additional cost:
Arrive early so you can attend the first half of the week, Feb. 27-28 for these conferences:
Get the Most Out of Your Budget with the "All Access Pass" to Attend Sessions from All 9 Conferences
View the Agenda-At-A-Glance for the Entire Week.
Special Discounted Hotel Rate Available Until February 3, 2012.
To book your room, call 1-800-HILTONS and mention that you are an IBC attendee at this event.
Read a sample of who attended the conference in 2011.
Updated: March 16, 2011
The Antibody Development & Production conference offers you the highest quality and most in-depth coverage of the latest technical and scientific advances in bioprocessing to help companies (of all sizes) improve the speed, quality and cost of developing and producing antibodies. Exclusive case studies delivering the latest data together with strategic discussion forums allow the industry's leading scientists, engineers and executives to collectively collaborate and provide solutions to their most pressing challenges.
"IBC continues to put together a well organized series of conferences that cover the key topics and areas of interest across the biotech industry. They provide an excellent forum to bring together leading scientists and companies to exchange ideas and create networking contacts." - William D. Taylor, Director, Business Development, Pfenex
Comparability Within A Single Product Differs from Biosimilarity Between Two Products
Anthony S. Lubiniecki, Sc.D.
Johnson & Johnson Pharmaceutical R&D, Inc.
Path to Approval for Antibody Drug Conjugates
Morris Rosenberg, D.Sc.
Seattle Genetics
Continuous Bioprocessing for Production of Biopharmaceuticals
Weichang Zhou, Ph.D.
Genzyme, a Sanofi Company
Application of Quality by Design Approach in Viral Clearance Studies: Be Prepared and Set a Realistic Expectation
Dayue Chen, Ph.D.
Eli Lilly and Company
Developing High Dose Monoclonal Antibody Formulations for SC Delivery
Steven J. Shire, Ph.D.
Genentech, Inc.
Special thanks to the Scientific Advisory Committee for their help in developing this program.
» View the list of committee members